Associated tags: NK, Therapy, Patient, Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, FDA, Pharmaceutical industry, Research, General Health
Locations: CAR, ITALY, CA, SAN FRANCISCO, UNITED STATES, NORTH AMERICA, NEW YORK, NEW JERSEY, NY, EC, EUROPE, BELGIUM, BRAZIL
Research,
Finance,
FDA,
Clinical Trials,
Professional Services,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Conference,
Webcast Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m.
Key Points:
- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, NY on Thursday, June 6, 2024, at 10:30 a.m.
- ET.
- The live webcast will be available to investors and other interested parties by accessing the Investor Relations section of Legend’s website.
- The webcast replay will be available approximately 48 hours after the webcast.
Research,
Other Health,
General Health,
Pharmaceutical,
Oncology,
Clinical Trials,
Science,
Neurology,
Biotechnology,
Nursing,
FDA,
Health,
Other Science Secondary hematological malignancies, including myelodysplastic syndrome and acute myeloid leukemia, have occurred in patients following treatment with CARVYKTI ®.
Key Points:
- Secondary hematological malignancies, including myelodysplastic syndrome and acute myeloid leukemia, have occurred in patients following treatment with CARVYKTI ®.
- Among patients receiving CARVYKTI® for RRMM in the CARTITUDE-1 & 4 studies (N=285), CRS occurred in 84% (238/285), including ≥ Grade 3 CRS (ASCT 2019) in 4% (11/285) of patients.
- The most common manifestations of CRS in all patients combined (≥ 10%) included fever (84%), hypotension (29%) and aspartate aminotransferase increased (11%).
- CRS occurred in 78% of patients in CARTITUDE-4 (3% Grade 3 to 4) and in 95% of patients in CARTITUDE-1 (4% Grade 3 to 4).
Biotechnology,
Health,
Pharmaceutical,
Cardiology,
Oncology,
Partnership,
Lenalidomide,
Data collection,
Patient,
Novartis,
ESG,
ANVISA,
Social,
Investment,
Johnson & Johnson,
Disease,
European Commission,
Medication,
Multiple myeloma,
Growth,
Janssen,
DLL3,
Development,
Research,
Biophysical environment,
Webcast,
Disclosure,
Brazilian Health Regulatory Agency,
Pharmaceutical industry Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2024 unaudited financial results and key corporate highlights.
Key Points:
- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its first quarter 2024 unaudited financial results and key corporate highlights.
- “Legend made great progress in the first quarter, culminating in our exciting announcements in recent weeks.
- Collaboration Revenue: Collaboration revenue was $78.5 million for the first quarter of 2024 compared to $36.3 million for the first quarter of 2023.
- Administrative Expenses: Administrative expenses were $31.9 million for the first quarter of 2024 compared to $22.2 million for the first quarter of 2023.
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®.
Key Points:
- Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®.
- Secondary hematological malignancies, including myelodysplastic syndrome and acute myeloid leukemia, have occurred in patients following treatment with CARVYKTI®.
- T-cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies, including CARVYKTI®.
- In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS.
Nursing,
Biotechnology,
FDA,
Professional Services,
Health,
Pharmaceutical,
Oncology,
Research,
Science,
Clinical Trials,
Finance,
News,
Webcast Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
Key Points:
- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Monday, May 13, 2024, to review first-quarter 2024 results.
- During the webcast and conference call, senior leaders will provide an overview of Legend Biotech’s performance for the quarter.
- A replay version of the webcast and earnings news release will be available through the Investor Relations section of Legend Biotech’s website under the Events and Presentation section approximately two hours after the call concludes.
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®.
Key Points:
- Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®.
- T-cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies, including CARVYKTI®.
- The median time to onset of myeloid neoplasms was 447 days (range: 56 to 870 days) after treatment with CARVYKTI®.
- T-cell malignancies have occurred following treatment of hematologic malignancies with BCMA- and CD19-directed genetically modified autologous T-cell immunotherapies, including CARVYKTI®.
Research,
Nursing,
FDA,
Clinical Trials,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Organization,
Medication,
Biophysical environment,
ESG,
Patient,
Hospital,
Disclosure,
Social,
Data collection,
Safety,
EHS,
Workplace,
Pharmaceutical industry Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social & Governance (ESG) report .
Key Points:
- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today released its inaugural Environmental, Social & Governance (ESG) report .
- “At Legend Biotech, we are united by our mission to deliver life-saving treatments to patients with intractable and incurable diseases.
- “We are proud to share our inaugural ESG report, highlighting our commitment to patients, employees, and our communities.
- Legend Biotech is proud to report that, based on its most recent annual employee engagement survey, 85% of employees feel their work is meaningful.
The committee provides non-binding recommendations based on its evaluation; final decisions on approval of the drug are made by the FDA.
Key Points:
- The committee provides non-binding recommendations based on its evaluation; final decisions on approval of the drug are made by the FDA.
- Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®.
- CYTOKINE RELEASE SYNDROME (CRS) including fatal or life-threatening reactions, occurred following treatment with CARVYKTI® in 95% (92/97) of patients receiving ciltacabtagene autoleucel.
- Grade 3 or higher CRS (2019 ASTCT grade) occurred in 5% (5/97) of patients, with Grade 5 CRS reported in 1 patient.
Research,
FDA,
Clinical Trials,
Other Health,
Biotechnology,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
Johnson & Johnson,
Growth,
Drug discovery,
Exercise,
Partnership,
Webcast,
Patient,
Committee,
Collaboration,
Nature,
Senior,
Lenalidomide,
Investment,
Investigational New Drug,
Delta,
ODAC,
Janssen,
CHMP,
Food Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights.
Key Points:
- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its fourth quarter and full year 2023 unaudited financial results and key corporate highlights.
- Financial Results for Quarter and Year Ended December 31, 2023
As of December 31, 2023, Legend Biotech had approximately $1.3 billion of cash and cash equivalents, time deposits, and short-term investments.
- There was no license revenue for the three months ended December 31, 2023, and December 31, 2022.
- License revenue for the year ended December 31, 2023, was $35.2 million, compared to $50.0 million for the year ended December 31, 2022.
Retrieved on:
Friday, February 23, 2024
The positive opinion from the CHMP will now be reviewed by the European Commission which renders the final decision on approval.
Key Points:
- The positive opinion from the CHMP will now be reviewed by the European Commission which renders the final decision on approval.
- Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with CARVYKTI®.
- CYTOKINE RELEASE SYNDROME (CRS) including fatal or life-threatening reactions, occurred following treatment with CARVYKTI® in 95% (92/97) of patients receiving ciltacabtagene autoleucel.
- In patients with progressive symptoms of CRS or refractory CRS despite treatment, evaluate for evidence of HLH/MAS.
